Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Cecilia C. Ayala-Aguilera, Teresa Valero, Álvaro Lorente‐Macías, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 1047-1131
Open Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Robert Roskoski
Pharmacological Research (2022) Vol. 187, pp. 106552-106552
Open Access | Times Cited: 236
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed M. Shawky, Faisal A. Almalki, Ashraf N. Abdalla, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1001-1001
Open Access | Times Cited: 193
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Robert Roskoski
Pharmacological Research (2024) Vol. 200, pp. 107059-107059
Open Access | Times Cited: 146
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Feng Ren, Alex Aliper, Jian Chen, et al.
Nature Biotechnology (2024)
Open Access | Times Cited: 74
Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions
Jindi Huang, Liye Chen, Jiangxia Wu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16033-16061
Closed Access | Times Cited: 72
Protein kinases: drug targets for immunological disorders
Leslie Castelo‐Soccio, Hanna Kim, Massimo Gadina, et al.
Nature reviews. Immunology (2023) Vol. 23, Iss. 12, pp. 787-806
Open Access | Times Cited: 53
Rule of five violations among the FDA-approved small molecule protein kinase inhibitors
Robert Roskoski
Pharmacological Research (2023) Vol. 191, pp. 106774-106774
Open Access | Times Cited: 45
Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs
Girish Chandra, Durg Vijay Singh, Gopal Kumar Mahato, et al.
Chemical Papers (2023) Vol. 77, Iss. 8, pp. 4085-4106
Open Access | Times Cited: 44
A review: FDA-approved fluorine-containing small molecules from 2015 to 2022
Negar Sheikhi, Maryam Bahraminejad, Mina Saeedi, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115758-115758
Closed Access | Times Cited: 42
Chemoproteomics Identifies State-Dependent and Proteoform-Selective Caspase-2 Inhibitors
José O. Castellón, Samuel Ofori, Nikolas R. Burton, et al.
Journal of the American Chemical Society (2024) Vol. 146, Iss. 22, pp. 14972-14988
Closed Access | Times Cited: 15
4,6-Disubstituted pyrimidine-based microtubule affinity-regulating kinase 4 (MARK4) inhibitors: synthesis, characterization, in-vitro activity and in-silico studies
Ashanul Haque, Khalaf M. Alenezi, Mohd. Saeed Maulana Abdul Rasheed, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access | Times Cited: 1
Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
Robert Roskoski
Pharmacological Research (2022) Vol. 183, pp. 106362-106362
Closed Access | Times Cited: 60
Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review
Jia Zheng, Wei Zhang, Linfeng Li, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 50
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 1
Nicholas A. Meanwell, Olivier Loiseleur
Journal of Agricultural and Food Chemistry (2022) Vol. 70, Iss. 36, pp. 10942-10971
Closed Access | Times Cited: 45
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Maria Reinecke, P. Brear, Larsen Vornholz, et al.
Nature Chemical Biology (2023) Vol. 20, Iss. 5, pp. 577-585
Open Access | Times Cited: 36
The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies
George Mihai Niţulescu, Gheorghe Stancov, Oana Cristina Șeremet, et al.
Molecules (2023) Vol. 28, Iss. 14, pp. 5359-5359
Open Access | Times Cited: 33
Applications of palladium-catalyzed C–N cross-coupling reactions in pharmaceutical compounds
Reza Emadi, Abbas Bahrami Nekoo, Fatemeh Molaverdi, et al.
RSC Advances (2023) Vol. 13, Iss. 27, pp. 18715-18733
Open Access | Times Cited: 27
The role of the methoxy group in approved drugs
Debora Chiodi, Yoshihiro Ishihara
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116364-116364
Closed Access | Times Cited: 11
Kinase Inhibitors FDA Approved 2018–2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities
Bethany D. Latham, Raeanne M. Geffert, Klarissa D. Jackson
Drug Metabolism and Disposition (2024) Vol. 52, Iss. 6, pp. 479-492
Open Access | Times Cited: 8
Protein phosphorylation and kinases: Potential therapeutic targets in necroptosis
Yihui Shi, Chengkun Wu, Jiayi Shi, et al.
European Journal of Pharmacology (2024) Vol. 970, pp. 176508-176508
Closed Access | Times Cited: 8
Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective
Qiangsheng Zhu, Nannan Chen, Xinjian Tian, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 12, pp. 8065-8090
Closed Access | Times Cited: 34
Harnessing systematic protein–ligand interaction fingerprints for drug discovery
Zheng Zhao, Philip E. Bourne
Drug Discovery Today (2022) Vol. 27, Iss. 10, pp. 103319-103319
Closed Access | Times Cited: 31
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules
Georg L. Goebel, Xiaqiu Qiu, Peng Wu
Trends in Pharmacological Sciences (2022) Vol. 43, Iss. 10, pp. 866-881
Closed Access | Times Cited: 28
Synthesis of novel pyrido[2,3-d]pyrimidine-thiazolidine-1,2,3-triazoles: Potent EGFR targeting anticancer agents
Sandhya Rani Bandi, Ravikumar Kapavarapu, Rambabu Palabindela, et al.
Journal of Molecular Structure (2023) Vol. 1294, pp. 136451-136451
Closed Access | Times Cited: 20
How many kinases are druggable? A review of our current understanding
Brian Anderson, Peter Rosston, Han Wee Ong, et al.
Biochemical Journal (2023) Vol. 480, Iss. 16, pp. 1331-1363
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top